Bristol-Myers Debt to Equity

BMYMP
 Stock
  

USD 1,287  0.00  0.00%   

Bristol-Myers Squibb fundamentals help investors to digest information that contributes to Bristol-Myers Squibb's financial success or failures. It also enables traders to predict the movement of Bristol-Myers OTC Pink Sheet. The fundamental analysis module provides a way to measure Bristol-Myers Squibb's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bristol-Myers Squibb otc pink sheet.
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.
  

Bristol-Myers Debt to Equity Analysis

Bristol-Myers Squibb's Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
D/E 
 = 
Total Debt 
Total Equity 
More About Debt to Equity | All Equity Analysis

Current Bristol-Myers Squibb Debt to Equity

    
  59.40 %  
Most of Bristol-Myers Squibb's fundamental indicators, such as Debt to Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bristol-Myers Squibb is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Compare to competition

According to the company disclosure, Bristol-Myers Squibb has a Debt to Equity of 59%. This is 10.95% higher than that of the Healthcare sector and 45.69% lower than that of the Drug Manufacturers - Major industry. The debt to equity for all United States stocks is 21.97% lower than that of the firm.

Bristol-Myers Debt to Equity Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bristol-Myers Squibb's direct or indirect competition against its Debt to Equity to detect undervalued stocks with similar characteristics or determine the otc pink sheets which would be a good addition to a portfolio. Peer analysis of Bristol-Myers Squibb could also be used in its relative valuation, which is a method of valuing Bristol-Myers Squibb by comparing valuation metrics of similar companies.
Bristol-Myers Squibb is currently under evaluation in debt to equity category among related companies.

Bristol-Myers Fundamentals

About Bristol-Myers Squibb Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bristol-Myers Squibb's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bristol-Myers Squibb using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bristol-Myers Squibb based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York. Bristol Myers operates under Drug Manufacturers - Major classification in USA and is traded on OTC Market. It employs 23700 people.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Bristol-Myers Squibb without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Portfolio Volatility Now

   

Portfolio Volatility

Check portfolio volatility and analyze historical return density to properly model market risk
All  Next Launch Module

Pair Trading with Bristol-Myers Squibb

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bristol-Myers Squibb position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bristol-Myers Squibb will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to Bristol-Myers Squibb could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bristol-Myers Squibb when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bristol-Myers Squibb - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bristol-Myers Squibb to buy it.
The correlation of Bristol-Myers Squibb is a statistical measure of how it moves in relation to other equities. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bristol-Myers Squibb moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bristol-Myers Squibb moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bristol-Myers Squibb can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Continue to Bristol-Myers Squibb Piotroski F Score and Bristol-Myers Squibb Altman Z Score analysis. You can also try Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.

Complementary Tools for analysis

When running Bristol-Myers Squibb price analysis, check to measure Bristol-Myers Squibb's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bristol-Myers Squibb is operating at the current time. Most of Bristol-Myers Squibb's value examination focuses on studying past and present price action to predict the probability of Bristol-Myers Squibb's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Bristol-Myers Squibb's price. Additionally, you may evaluate how the addition of Bristol-Myers Squibb to your portfolios can decrease your overall portfolio volatility.
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
Portfolio Anywhere
Track or share privately all of your investments from the convenience of any device
Go
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Portfolio Diagnostics
Use generated alerts and portfolio events aggregator to diagnose current holdings
Go
Stock Screener
Find equities using custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
Go
Please note, there is a significant difference between Bristol-Myers Squibb's value and its price as these two are different measures arrived at by different means. Investors typically determine Bristol-Myers Squibb value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bristol-Myers Squibb's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.